| Revenue growth | 47% YoY consolidated growth in FY26. |
|---|---|
| Margins | EBITDA at ₹8,219 Lakhs for MDx division. |
| Demand visibility | Strong MDx demand; 15% domestic market share. |
| Management confidence | High; targeting 15-20% growth in FY27. |
Growth
FY26 Consolidated Revenue grew 47% YoY to ₹14,191 Lakhs; Consolidated PAT rose 25.6% to ₹5,992 Lakhs.
Outlook
Management guides 15-20% growth for FY27. Ongoing 'Sample to Answer' system development and IVDR certification pursuit.
Risks
Geopolitical tensions in Bangladesh and Middle East caused export de-growth and order cancellations in specific segments.
Earnings Call filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,463.50
- Market cap
- ₹1,256 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹58.59 Cr
- P/E (TTM)
- 22.6×Sector 37.5×
- Promoter holding
- 40.95%+0.01% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B BlackBio Dx Investor Presentation: Key Takeaways
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
- Call
- Guides 18% growth
3B BlackBio Dx Q1 FY27 Results: Net Profit ₹9 Cr, Down 28.6% YoY
3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹9 Cr · -28.6% YoY
3B BlackBio Dx Earnings Call: Key Takeaways
3B BlackBio reported FY26 consolidated revenue of ₹142 cr and PAT of ₹60 cr, driven by diagnostic growth and contributions from Coris BioConcept and TRUPCR Europe.